UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 11, 2016
RELYPSA, INC.
(Exact name of registrant as specified in its charter)
| Delaware | 001-36184 | 26-0893742 | ||
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification Number) |
100 Cardinal Way
Redwood City, CA 94063
(Address of principal executive offices, including Zip Code)
Registrant’s telephone number, including area code: (650) 421-9500
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 8.01. Other Events.
Relypsa, Inc. (the “Company”) discloses herein the new patient starts, outpatient prescriptions and units sold to hospitals/other institutions for the full month of June 2016 and three-month period ended June 30, 2016 for Veltassa® (patiromer) for oral suspension (“Veltassa”).
These numbers have not been verified by any third party and represent the Company’s estimates as of the date indicated. The Company assumes no obligation to update them.
June 1-30, 2016
In the outpatient setting:
| • | 1,531 new patients started taking Veltassa with a free starter supply. |
| • | 1,723 outpatient prescriptions were covered by payers and dispensed (retail TRx). |
In the hospital/institution setting:
| • | 392 units were sold to hospitals and other institutions (non-retail). |
Overall Quarterly Numbers
Outpatient setting*
April 1-30, 2016 | May 1-31, 2016 | June 1-30, 2016 | Q2 2016 Total | |||||
New patients who started taking Veltassa with a free starter supply | 1,216 (average 290 patients/week) | 1,385 (average 330 patients/week) | 1,531 (average 348 patients/week) | 4,132 | ||||
Outpatient prescriptions covered and dispensed (retail TRx) | 928 (average 221 prescriptions/week) | 1,230 (average 293 prescriptions/week) | 1,723 (average 392 prescriptions/week) | 3,881 | ||||
Hospital/institution setting*
April 1-30, 2016 | May 1-31, 2016 | June 1-30, 2016 | Q2 2016 Total | |||||
Hospital/institution units sold (non-retail) | 288 (average 69 units/week) | 277 (average 66 units/week) | 392 (average 89 units/week) | 957 | ||||
| * | Weekly averages were calculated assuming 4.2 weeks in April and May, and 4.4 weeks in June. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: July 11, 2016 | RELYPSA, INC. | |||||
| By: | /s/ Kristine M. Ball | |||||
| Senior Vice President and Chief Financial Officer | ||||||
